Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Chagas disease 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
2 Chagas disease 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
3 Chagas disease 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
4 Chagas disease 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
5 Chagas disease 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
6 Chagas disease 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
7 Chagas disease 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
8 Chagas disease 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
9 Chagas disease 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
10 Chagas disease 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
11 Epstein-Barr virus infection 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
12 Epstein-Barr virus infection 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
13 Epstein-Barr virus infection 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
14 Epstein-Barr virus infection 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
15 Epstein-Barr virus infection 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
16 Epstein-Barr virus infection 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
17 Epstein-Barr virus infection 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
18 Epstein-Barr virus infection 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
19 Epstein-Barr virus infection 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
20 Epstein-Barr virus infection 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
21 Hematopoietic cell lineage 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
22 Hematopoietic cell lineage 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
23 Hematopoietic cell lineage 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
24 Hematopoietic cell lineage 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
25 Hematopoietic cell lineage 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
26 Hematopoietic cell lineage 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
27 Hematopoietic cell lineage 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
28 Hematopoietic cell lineage 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
29 Hematopoietic cell lineage 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
30 Hematopoietic cell lineage 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
31 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
32 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
33 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
34 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
35 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
36 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
37 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
38 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
39 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
40 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
41 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
42 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
43 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
44 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
45 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
46 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
47 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
48 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
49 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
50 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
51 Measles 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
52 Measles 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
53 Measles 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
54 Measles 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
55 Measles 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
56 Measles 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
57 Measles 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
58 Measles 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
59 Measles 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
60 Measles 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
61 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
62 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
63 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
64 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
65 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
66 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
67 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
68 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
69 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
70 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
71 Primary immunodeficiency 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
72 Primary immunodeficiency 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
73 Primary immunodeficiency 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
74 Primary immunodeficiency 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
75 Primary immunodeficiency 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
76 Primary immunodeficiency 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
77 Primary immunodeficiency 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
78 Primary immunodeficiency 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
79 Primary immunodeficiency 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
80 Primary immunodeficiency 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
81 T cell receptor signaling pathway 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
82 T cell receptor signaling pathway 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
83 T cell receptor signaling pathway 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
84 T cell receptor signaling pathway 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
85 T cell receptor signaling pathway 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
86 T cell receptor signaling pathway 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
87 T cell receptor signaling pathway 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
88 T cell receptor signaling pathway 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
89 T cell receptor signaling pathway 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
90 T cell receptor signaling pathway 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
91 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
92 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
93 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
94 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
95 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
96 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
97 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
98 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
99 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
100 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
101 Th17 cell differentiation 💬
1件: CD3E 💬 Anti-human thymocyte immunoglobulin, rabbit 💬 Antithymocyte immunoglobulin (rabbit) 13件: 13, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286, 326 💬
102 Th17 cell differentiation 💬
1件: CD3E 💬 Blinatumomab 💬 Blinatumomab 3件: 11, 46, 49 💬
103 Th17 cell differentiation 💬
1件: CD3E 💬 Elranatamab 💬 Elranatamab 1件: 28 💬
104 Th17 cell differentiation 💬
1件: CD3E 💬 Imvotamab 💬 Imvotamab 2件: 46, 49 💬
105 Th17 cell differentiation 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
106 Th17 cell differentiation 💬
1件: CD3E 💬 Muromonab-CD3 💬 Muromonab 3件: 60, 96, 97 💬
107 Th17 cell differentiation 💬
1件: CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
108 Th17 cell differentiation 💬
1件: CD3E 💬 Talquetamab 💬 Talquetamab 1件: 28 💬
109 Th17 cell differentiation 💬
1件: CD3E 💬 Teclistamab 💬 Teclistamab 1件: 28 💬
110 Th17 cell differentiation 💬
1件: CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬